SPECIAL CONTRIBUTION Targeted Therapy of Cancer with Radiolabeled Antibodies

This review focuses on the use of radiolabeled antibodies in the therapy of cancer, termed radioimmunotherapy (RAIT). Basic problems concerning the choice of antibody and radionuclide and the physiology of tumor and host are discussed. Then follows a review of pertinent clinical publications on various radioantibody constructs in the treatment of hematopoietic and solid tumors of diverse histopathologies, grades, and stages, and in different clinical settings. Factors such as dose rate delivered, tumor size, and radiosensitivity play a major role in determining therapeutic response, while target-to-nontarget ra-tios and, particularly, circulating radioactivity to the bone mar-row determine the major dose-limiting toxicities. RAIT appears to be gaining a place in the therapy of hematopoietic neo-plasms, such as non-Hodgkin’s lymphoma, with several agents advancing in clinical trials toward registration, of which one ha